INTRODUCTION AND OBJECTIVES: Since 2013, both the United States Preventive Services Task Force and the Kaiser Permanente National Prostate Cancer Guidelines have recommended against PSA-based screening for prostate cancer in men >70 years of age. Adherence to these guidelines has been variable. A "Best Practice Alert" (BPA) was activated in the electronic medical record (EMR) system in October 2015 at Kaiser Permanente Northern California (KPNC). This alerted physicians, in real time, if they attempted to order a PSA test in a man >70 years of age with no history of prostate cancer. No additional physician training or education was used. The objective of the present study was to determine the impact of this BPA on the frequency of inappropriate PSA testing.
METHODS: This was a retrospective study spanning the years 2013 to 2017, in men >70 years of age in KPNC with no prior history of prostate cancer. We compared the annual rates of PSA testing between the pre-BPA period, 2013 and 2014; and the post-BPA period, 2016 and 2017 (the post-BPA period began 3 months after the BPA was instituted). The primary outcome was the annual rate of PSA testing. The percent change between the two time periods, the rate ratio and 95% confidence interval (CI) were calculated.
RESULTS: The annual number of eligible men (men >70 years of age and no history of prostate cancer) and annual number of these men undergoing PSA testing are shown in the Table. Annual screening rates declined from 34.3% in the pre-BPA era to 13.5% in the post BPA era. The rate ratio was 0.394 (95% CI, 0.390-0.398).
CONCLUSIONS: Following the activation of a simple and inexpensive BPA within the EMR, the rate of inappropriate PSA testing decreased 61% in men >70 years of age. This change was durable over the study period, demonstrating that well-conceived, straightforward interventions can have a marked effect on physician behavior. (ERSPC) . The objective of this study was to assess the contribution of treatment differences on the observed prostate cancer mortality reduction between the screening arm and control arm.
Source of
METHODS: We analyzed a total of 14,136 men with prostate cancer (7,310 men in the screening arm: 6,826 in the control arm) in the core age group (55-69 years) at 16 years of follow-up. We compared the observed versus estimated number of prostate cancer deaths by treatment allocation in the screening arm and control arm, respectively. Treatment allocation was modeled using multinomial logistic regression adjusting for: center, age, year, prostate-specific antigen level, Gleason score, and TNM stage. For each treatment, logistic regression models were fitted for risk of prostate cancer death, separately for the screening arm and control arm, and using the same covariates as for the treatment allocation model. Treatment probabilities were multiplied with estimated prostate cancer death risks for each treatment based on one arm, summed and compared to the observed number of deaths.
RESULTS: The difference between the estimated and observed treatment distributions in the screening arm and control arm was marginal and ranged between -3.3% and 3.3%. The difference in the estimated and observed number of prostate cancer deaths was small: 0.01% (95% CI -0.28%, 0.24%) when comparing the estimated screening arm model to the observed number of prostate cancer deaths in the control arm, and 0.05% (95% CI -0.11%, 0.18%) when comparing the estimated control arm model to the observed number of prostate cancer deaths in the screening arm. A limitation of this study is that only data on primary treatment was available.
CONCLUSIONS: This study supports the notion that the effectiveness of PSA-screening in reducing prostate cancer mortality in the ERSPC trial is due to early detection, allowing for effective management, and is not attributable to differential treatment between trial arms. 
